Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
06/2003
06/17/2003US6579972 An antibody having a specific binding affinity to a polypeptide of given amino acid sequence; can use in treating diabetes, skeletal muscle diseases, Alzheimer's disease, or peripheral neuropathies with an agonist or antagonist
06/17/2003US6579970 Specific octapeptides, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds and immune effector cells raised in response to presentation of these epitopes.
06/17/2003US6579969 Purified polypeptide of given amino acid sequence; serine/threonine kinase
06/17/2003US6579850 Polypeptide, novel DNA and novel antibody
06/17/2003US6579848 Treating hyperpigmentation with melanin production inhitors peptide
06/17/2003US6579709 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/17/2003US6579696 Comprising diaminobutyric acid having a gamma amino group and amino acid selected from cysteine, alanine and lysine; use in prevention and treatment of sepsis
06/17/2003US6579691 DNA sequence encoding a neuronal protein kinase (NPK) which phosphorylates tau proteins as well as other microtubule associated proteins (MAPs) in positions crucial for the binding to microtubules, alzheimers disease, antitumor
06/17/2003US6579684 Assay of YKL-40 as a marker for cancer
06/17/2003US6579683 A ligand which is a member of Ephrin family of Eph family receptor interactive protein has been shown to be expressed by arterial endothelial cells but not by venous endothelial cell, useful for distinguishing target artieris and veins
06/17/2003US6579678 Identifying evolved polynucleotides using recursive sequence recombination; recombining overlapping nucleotide sequences; screening for desired property; use in correlating different combinations of mutations with a desired result
06/17/2003US6579527 Recombinant Pallas's cat FIV (FIV-Oma) virus, FIV-Oma3; vectors; antigens have broad specificity for immunization of cats; also use in diagnosis
06/17/2003US6579526 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
06/17/2003CA2129820C Dna sequences encoding novel growth/differentiation factors
06/17/2003CA2118816C Composition for introducing nucleic acid complexes into higher eucaryotic cells
06/17/2003CA2100462C Non-depleting cd4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (iddm)
06/17/2003CA2072249C Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
06/17/2003CA2046654C Radiolabeled proteins for diagnostic or therapeutic use
06/17/2003CA1341431C Immunotherapy for aids patients
06/12/2003WO2003049117A2 Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection
06/12/2003WO2003048779A1 Method for detecting allergies and use of an antibody to detect allergies
06/12/2003WO2003048384A2 Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
06/12/2003WO2003048378A2 Methods and compositions for selectively cleaving dna containing duplex acids in a complex nucleic acid mixture
06/12/2003WO2003048376A2 Modulation of immune-cell related disorders using il-1hy2
06/12/2003WO2003048359A1 Markers for sugar/lipid metabolic disorders and utilization thereof
06/12/2003WO2003048349A2 Acetoacetyl-coa thiolase and use of for the identification of novel fungicidal substances
06/12/2003WO2003048337A2 Antibody to latent membrane proteins and uses thereof
06/12/2003WO2003048334A2 Immunocytokines with modulated selectivity
06/12/2003WO2003048328A2 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
06/12/2003WO2003048327A2 Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection
06/12/2003WO2003048321A2 Hybrid antibodies
06/12/2003WO2003048317A2 Antibodies to magmas and uses thereof
06/12/2003WO2003048306A2 Polycistronic expression of antibodies
06/12/2003WO2003048303A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/12/2003WO2003048302A2 Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
06/12/2003WO2003048301A2 Anti-hla-dr antibodies and the methods of using thereof
06/12/2003WO2003048209A1 Bispecific anti-cd19 x anti-cd16 antibodies and uses thereof
06/12/2003WO2003048208A2 Expression control using variable intergenic sequences
06/12/2003WO2003048207A2 Anti-dota antibody
06/12/2003WO2003048205A2 Novel proteins with il-6 inhibiting activity
06/12/2003WO2003048204A1 Alzheimer’s disease-associated gene and protein and use thereof
06/12/2003WO2003048200A1 Nuclear protein 'shoca' - a component of the wnt signalling pathway
06/12/2003WO2003048199A1 Cytotoxic protein and utilization thereof
06/12/2003WO2003048193A2 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN
06/12/2003WO2003048166A1 Podophyllotoxins as antiproliferative agents
06/12/2003WO2003048083A2 Antibodies against monocyte chemotactic proteins
06/12/2003WO2003047623A1 Treatment of prostate cancer by inhibitors of ncam2
06/12/2003WO2003047622A1 Remedies for multiple sclerosis
06/12/2003WO2003047621A1 CELL PROLIFERATION INHIBITOR CONTAINING ANTI-PepT ANTIBODY
06/12/2003WO2003047620A2 Compositions and methods for producing vascular occlusion
06/12/2003WO2003047514A2 Reducing myelin-mediated inhibition of axon regeneration
06/12/2003WO2003047510A2 Anti-tnf antibodies, compositions, methods and uses
06/12/2003WO2003047506A2 Peptide agonists of prostate-specific antigen, and uses therefor
06/12/2003WO2003047421A2 Methods and reagents for diagnosis and treatment of diabetes
06/12/2003WO2003047420A2 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
06/12/2003WO2003047336A2 TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
06/12/2003WO2003038098A3 5t4 ligand
06/12/2003WO2003027282A9 Adamts-15, -16, -17, -18 and -19
06/12/2003WO2002057465A3 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs
06/12/2003WO2002046435A3 Engineered plasmids and their use for in situ production of genes
06/12/2003WO2002012345A3 Soluble zcytor 11 cytokine receptors
06/12/2003US20030110519 Cognition activators, sleep disorders, eating disorders, psychological disorders
06/12/2003US20030109691 Variant integrin polypeptides and uses thereof
06/12/2003US20030109689 Using polypeptides; induction immunology response
06/12/2003US20030109681 Polypeptide binding to antibody
06/12/2003US20030109680 Anticoagulants; angiogenesis inhibitors
06/12/2003US20030109674 Antiinflammatory agents; medical diagnosis; genetic engineered polypeptide
06/12/2003US20030109672 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/12/2003US20030109469 Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
06/12/2003US20030109445 Methods and compositions for the treatment and prevention of parkinson's disease
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109416 methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.
06/12/2003US20030109042 Stimulant immunology system; cell differentiation; culture product; three-dimensional support
06/12/2003US20030109041 Culture regeneration of nervous systems; cell differentiation; wound healing agent
06/12/2003US20030109039 Enriched central nervous system stem cell and porgenitor cell populations, and methods for identifying, isolating and enriching for such populations
06/12/2003US20030109027 Tumor suppression genes
06/12/2003US20030109022 Asp2
06/12/2003US20030109018 Novel endometriosis-associated gene
06/12/2003US20030109016 Tumor suppresison gene; anticancer agents
06/12/2003US20030109006 Isolation of lymphocytes, binding, forming culture product, cloning
06/12/2003US20030109004 Culture product; cell transformation; genetic engineering using promoter
06/12/2003US20030109003 Antitumor agent; transformation of expression vector; genetic engineering; process control hybrids
06/12/2003US20030109002 SIRP proteins and uses thereof
06/12/2003US20030109000 Culture product; binding polypeptides containing activated end groups
06/12/2003US20030108998 Aggrecan degrading metallo proteases
06/12/2003US20030108996 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/12/2003US20030108984 CD44 splice variant associated with rheumatoid arthritis
06/12/2003US20030108983 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/12/2003US20030108971 Enzyme
06/12/2003US20030108970 Generating antibodies; quantitative analysis
06/12/2003US20030108967 Monoclonal antibodies against human apoptosis inhibitory protein NAIP and method for assaying the NAIP
06/12/2003US20030108966 Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof
06/12/2003US20030108965 Using polypeptide, detection of antibody; cancer of ovaries
06/12/2003US20030108961 Methods and compositions for diagnosing breast cancer
06/12/2003US20030108956 Measurement, calibration of potassium channel moderators
06/12/2003US20030108950 Measuring concentration in body fluid of tumor antibodies
06/12/2003US20030108948 Artificial antibody polypeptides
1 ... 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 ... 1494